|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin interviews several contract manufacturers and device developers who are responsible for creating next-generation parenteral drug delivery.
|
|
|
Michael J. LaBarre, PhD, discusses how the ENHANZE drug delivery technology has the potential to improve the pharmacokinetic profiles of co-administered drugs through increased dispersion, absorption, and bioavailability.
|
|
|
Marc Brown, PhD, Jon Lenn, PhD, and Jeremy Drummond, PhD, believe it is essential the lead (and potentially a back-up formulation depending on any risk factors identified) has been optimized and characterized to demonstrate it will maintain its quality and performance as well as provide the best chance of measurable success in the clinical setting.
|
|
|
Laurie L. Sullivan and Cheryl L. Barton, PhD, say as manufacturers expand the clinical utility and healthcare professionals become more familiar with their efficacy and safety profiles, the checkpoint inhibitor market will continue to expand, becoming the cornerstone of many cancer treatment regimens.
|
|
|
|
|
|
|
|
|

Backed by over 85 years of experience in parenterals, Baxter’s BioPharma Solutions (BPS) business collaborates with pharmaceutical companies to support commercialization objectives for their molecules. BPS is a premier CMO with a focus on injectable pharmaceutical manufacturing designed to meet complex and traditional sterile manufacturing challenges with confidence of delivery, service, and integrity. BPS can support your pharmaceutical needs with a broad portfolio of sterile fill/finish production capabilities, and our reputation is built on the high-quality products we manufacture for our clients in a cGMP environment. Click here for more.

West is a leading global manufacturer in the design and production of technologically advanced, high quality, integrated containment and delivery systems for injectable medicines. We are a trusted partner to the world’s top pharmaceutical and biotechnology companies – working by their side to improve patient health. West contract manufacturing harnesses a powerful combination of innovation, technology, infrastructure and expertise to serve the pharmaceutical, medical and consumer industries. Along with more than 40 years of experience, we bring customers quality, safety and reliability in injection molding, contract assembly and finished packaging from our eight locations throughout North America and Europe. Click here for more.
|
|
|
|
|
|
 |
|
Novo Nordisk recently announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for oral semaglutide, a glucagon-like peptide-1 (GLP-1) analogue in a tablet taken once-daily, for the treatment of adults with type 2 diabetes.
|
|
 |
|
Oculos and Optceutics recently announced they are entering into a co-promotion arrangement to provide broader services for clients spanning from early research through product approval.
|
|
 |
|
Caris Life Sciences recently announced it has acquired Pharmatech, Inc., a pioneer of the original Just-In-Time research system with the largest research-ready oncology network.
|
|
 |
|
AbbVie, a research-based global biopharmaceutical company, recently announced that the European Commission (EC) has approved SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
|
|
|
|
|
Upcoming eNewsletter Features:
May 15 – Parenteral Contrqact Manufacturing
May 22 – Nasal Drug Delivery
|
|
|
|
|
|
|
|